Mga Batayang Estadistika
| LEI | 529900A03D1G15M8WM72 |
| CIK | 1113148 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Infinity Pharmaceuticals Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| September 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 28, 2023 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) ( |
|
| September 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 12, 2023 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) ( |
|
| September 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2023 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (C |
|
| September 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2023 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Com |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| July 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Commi |
|
| July 25, 2023 |
Infinity Pharmaceuticals Announces Value Preservation and Maximization Plan Exhibit 99.1 Infinity Pharmaceuticals Announces Value Preservation and Maximization Plan CAMBRIDGE, Mass.-(BUSINESS WIRE)—July 25, 2023- Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a potential first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced a series of actions |
|
| July 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2023 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Commi |
|
| July 24, 2023 |
Exhibit 99.1 Infinity Pharmaceuticals Announces Termination of Merger Agreement with MEI Pharma Eganelisib Remains Primary Value Driver for Infinity Infinity to Explore Strategic Alternatives to Maximize Value for Stockholders CAMBRIDGE, Mass.-(BUSINESS WIRE)—July 24, 2023- Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”), a clinical-stage biotechnology company developing eganelisib, a p |
|
| July 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2023 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Commi |
|
| July 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| July 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| July 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ De |
|
| July 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2023 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Commis |
|
| July 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2023 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Commis |
|
| June 30, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 27, 2023 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Commi |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ De |
|
| June 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Commi |
|
| June 20, 2023 |
Exhibit 99.1 MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates Event Available at 8:00 a.m. Eastern Time on June 19, 2023 SAN DIEGO, CA. and CAMBRIDGE, MA., June 15, 2023 – MEI Pharma, Inc. (Nasdaq: MEIP) (“MEI”), a clinical-stage pharmaceutical company focused on advancing new therapie |
|
| June 20, 2023 |
Exhibit 99.1 MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates Event Available at 8:00 a.m. Eastern Time on June 19, 2023 SAN DIEGO, CA. and CAMBRIDGE, MA., June 15, 2023 – MEI Pharma, Inc. (Nasdaq: MEIP) (“MEI”), a clinical-stage pharmaceutical company focused on advancing new therapie |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ De |
|
| June 20, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Commi |
|
| June 20, 2023 |
Exhibit 99.2 JUNE 2023 MEI Pharma & Infinity Pharmaceuticals Merger and Clinical Program Update A Transaction with Potential to Create Significant Opportunities and Build Value 2 TODAY’S AGENDA Welcome and Overview David Urso, President & CEO (MEIP and combined company) Eganelisib Dr. Robert Ilaria, Jr., Chief Medical Officer (INFI and combined company) Dr. Ezra Cohen Chief Medical Officer, Oncolo |
|
| June 20, 2023 |
Exhibit 99.2 JUNE 2023 MEI Pharma & Infinity Pharmaceuticals Merger and Clinical Program Update A Transaction with Potential to Create Significant Opportunities and Build Value 2 TODAY’S AGENDA Welcome and Overview David Urso, President & CEO (MEIP and combined company) Eganelisib Dr. Robert Ilaria, Jr., Chief Medical Officer (INFI and combined company) Dr. Ezra Cohen Chief Medical Officer, Oncolo |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ De |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ De |
|
| June 6, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| May 9, 2023 |
THIS IS AN IMPORTANT LEGAL DOCUMENT. PLEASE CONFER WITH A LAWYER OR OTHER TRUSTED ADVISOR BEFORE SIGNING THIS DOCUMENT. February 23, 2023 VIA HAND DELIVERY Lawrence Bloch P.O. Box 650129 West Newton, MA 02465 Re: Severance Agreement and Release Dear Lawrence: This letter summarizes the terms of your separation from employment with Infinity Pharmaceuticals Inc (the “Company”). The purpose of this A |
|
| April 7, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 4, 2023 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Commi |
|
| March 28, 2023 |
1100 Massachusetts Avenue Cambridge, MA Tel: 617-453-1000 Fax: 617-453-1001 www.infi.com February 22, 2023 Robert Ilaria 1100 Massachusetts Avenue Cambridge, MA 02138 Dear Robert: As you know, Infinity Pharmaceuticals, Inc. (“Infinity”) is entering into a merger agreement with MEI Pharma, Inc. (“MEI”) by which, if the merger is completed in accordance with its terms, Infinity will become a subsidi |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 28, 2023 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Comm |
|
| March 28, 2023 |
1100 Massachusetts Avenue Cambridge, MA Tel: 617-453-1000 Fax: 617-453-1001 www.infi.com February 22, 2023 Seth Tasker 1100 Massachusetts Avenue Cambridge, MA 02138 Dear Seth: As you know, Infinity Pharmaceuticals, Inc. (“Infinity”) is entering into a merger agreement with MEI Pharma, Inc. (“MEI”) by which, if the merger is completed in accordance with its terms, Infinity will become a subsidiary |
|
| March 28, 2023 |
As filed with the Securities and Exchange Commission on March 28, 2023 As filed with the Securities and Exchange Commission on March 28, 2023 Registration No. |
|
| March 28, 2023 |
Amended and Restated Bylaws of the Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF INFINITY PHARMACEUTICALS, INC. ARTICLE I OFFICES Section 1. Registered Office. The registered office shall be in the City of Dover, County of Kent, State of Delaware. Section 2. Other Offices. The corporation may also have offices at such other places both within and without the State of Delaware as the Board of Directors may from time to time determine o |
|
| March 28, 2023 |
Exhibit 99.1 Infinity Pharmaceuticals Reports Full Year 2022 Financial Results – Infinity ended 2022 with total cash and cash equivalents of $38.3 million – – Infinity Previously Announced Definitive Merger Agreement with MEI Pharma to Advance Three Promising Clinical Oncology Candidates – CAMBRIDGE, Mass., March 28, 2023 /Business Wire/ - Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” |
|
| March 28, 2023 |
1100 Massachusetts Avenue Cambridge, MA Tel: 617-453-1000 Fax: 617-453-1001 www.infi.com February 22, 2023 Adelene Perkins 1100 Massachusetts Avenue Cambridge, MA 02138 Dear Adelene: As you know, Infinity Pharmaceuticals, Inc. (“Infinity”) is entering into a merger agreement with MEI Pharma, Inc. (“MEI”) by which, if the merger is completed in accordance with its terms, Infinity will become a subs |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-3114 |
|
| March 28, 2023 |
1100 Massachusetts Avenue Cambridge, MA Tel: 617-453-1000 Fax: 617-453-1001 www.infi.com February 22, 2023 Stéphane Peluso 1100 Massachusetts Avenue Cambridge, MA 02138 Dear Stéphane: As you know, Infinity Pharmaceuticals, Inc. (“Infinity”) is entering into a merger agreement with MEI Pharma, Inc. (“MEI”) by which, if the merger is completed in accordance with its terms, Infinity will become a sub |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 28, 2023 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Comm |
|
| March 28, 2023 |
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. |
|
| March 28, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Infinity Pharmaceuticals, Inc. |
|
| March 28, 2023 |
Exhibit 99.1 Infinity Pharmaceuticals Reports Full Year 2022 Financial Results – Infinity ended 2022 with total cash and cash equivalents of $38.3 million – – Infinity Previously Announced Definitive Merger Agreement with MEI Pharma to Advance Three Promising Clinical Oncology Candidates – CAMBRIDGE, Mass., March 28, 2023 /Business Wire/ - Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (C |
|
| February 23, 2023 |
Exhibit 99.2 MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising Clinical Oncology Candidates Combination will create a company with a diverse product development pipeline led by a planned new global Phase 2 clinical trial evaluating eganelisib in head and neck squamous cell carcinoma (HNSCC) Projected ~$100M cash balance of combined company expe |
|
| February 23, 2023 |
Exhibit 99.1 February 23, 2023 MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance 3 Promising Clinical Oncology Candidates 2 Cautionary Statement Regarding Forward-Looking Statements Certain statements contained in this filing may be considered forward-looking statements within the meaning of the federal securities law. Such statements are based upon current pl |
|
| February 23, 2023 |
Exhibit 3.1 Amendment to Amended and Restated Bylaws of Infinity Pharmaceuticals, Inc., effective February 22, 2023 The Amended and Restated Bylaws of Infinity Pharmaceuticals, Inc. be and hereby are amended by adding thereto a new Section 6 to Article IX thereof, as follows: “Section 6. Forum Selection By-law. (a) Unless the corporation consents in writing to the selection of an alternative forum |
|
| February 23, 2023 |
Exhibit 2.1 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. AGREEMENT AND PLAN OF MERGER among INFINITY PHARMACEUTICALS, INC., MEI PHARMA, INC. and MEADOW MERGER SUB, INC. Dated as of February 22, 2023 TABLE OF CONTENTS |
|
| February 23, 2023 |
Exhibit 3.1 Amendment to Amended and Restated Bylaws of Infinity Pharmaceuticals, Inc., effective February 22, 2023 The Amended and Restated Bylaws of Infinity Pharmaceuticals, Inc. be and hereby are amended by adding thereto a new Section 6 to Article IX thereof, as follows: “Section 6. Forum Selection By-law. (a) Unless the corporation consents in writing to the selection of an alternative forum |
|
| February 23, 2023 |
Exhibit 99.2 MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising Clinical Oncology Candidates Combination will create a company with a diverse product development pipeline led by a planned new global Phase 2 clinical trial evaluating eganelisib in head and neck squamous cell carcinoma (HNSCC) Projected ~$100M cash balance of combined company expe |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (C |
|
| February 23, 2023 |
Exhibit 2.1 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. AGREEMENT AND PLAN OF MERGER among INFINITY PHARMACEUTICALS, INC., MEI PHARMA, INC. and MEADOW MERGER SUB, INC. Dated as of February 22, 2023 TABLE OF CONTENTS |
|
| February 23, 2023 |
Exhibit 99.1 February 23, 2023 MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance 3 Promising Clinical Oncology Candidates 2 Cautionary Statement Regarding Forward-Looking Statements Certain statements contained in this filing may be considered forward-looking statements within the meaning of the federal securities law. Such statements are based upon current pl |
|
| February 23, 2023 |
Filed by Infinity Pharmaceuticals, Inc. Filed by Infinity Pharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Infinity Pharmaceuticals, Inc. Commission File No.: 000-31141 MEI Pharma MEI Pharma and Infinity Pharmaceuticals Merger Announcement Webcast February 23, 2023 at 8:00 a.m. Eastern C |
|
| February 14, 2023 |
INFI / Infinity Pharmaceuticals Inc. / Polar Capital Holdings Plc Passive Investment SC 13G/A 1 polar-infi123122a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Infinity Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 45665G303 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) C |
|
| February 9, 2023 |
INFI / Infinity Pharmaceuticals Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01141-infinitypharmaceutic.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Infinity Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 45665G303 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate |
|
| December 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 28, 2022 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (C |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 14, 2022 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (C |
|
| November 14, 2022 |
Exhibit 99.1 Infinity Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update – MARIO-3 Update in Patients with 1L TNBC showing 52% increase in one-year progression free survival rate in ITT patient population compared to Impassion130 benchmark – – Business development discussions advancing with goal of announcing a partnership in Q1 2023 – – Cash runway into 2024 |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| August 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 24, 2022 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Com |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| August 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 9, 2022 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Comm |
|
| August 9, 2022 |
Exhibit 99.1 Infinity Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update ? Positive eganelisib data from two-year landmark analysis demonstrate durable survival benefit in urothelial cancer (UC) patients from MARIO-275 ? ? MARIO-3 triple negative breast cancer (TNBC) data update on track by year end ? ? Further eganelisib clinical development stage gated on |
|
| June 16, 2022 |
2019 Equity Incentive Plan, as amended. Filed herewith. Exhibit 99.1 INFINITY PHARMACEUTICALS, Inc. 2019 EQUITY INCENTIVE PLAN 1. Purpose The purpose of this 2019 Equity and Incentive Plan (the ?Plan?) of Infinity Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), is to advance the interests of the Company?s stockholders by enhancing the Company?s ability to attract, retain and motivate persons who are expected to make important contributio |
|
| June 16, 2022 |
As filed with the Securities and Exchange Commission on June 16, 2022 S-8 1 brhc10038757s8.htm S-8 As filed with the Securities and Exchange Commission on June 16, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Infinity Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 33-0655706 (State or Other Jurisdiction of Inco |
|
| June 16, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) INFINITY PHARMACEUTICALS, INC. |
|
| June 16, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 16, 2022 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Commi |
|
| May 24, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 24, 2022 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Commis |
|
| May 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 3, 2022 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Commiss |
|
| May 3, 2022 |
Exhibit 99.1 Infinity Pharmaceuticals Reports First Quarter 2022 Financial Results ? MARIO-4, the first eganelisib registration-enabling trial, in front-line metastatic triple negative breast cancer (TNBC) expected to initiate by year-end 2022 ? ? MARIO-P, a clinical program designed to expand eganelisib development in additional solid tumor indications, is planned to start in 3Q2022 ? ? Investor |
|
| May 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| April 25, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.?) Filed by the Registrant ? ? ? Filed by a party other than the Registrant ?? Check the appropriate box: ?? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission Only (as permi |
|
| March 29, 2022 |
Amendment No. 1 to 2019 Equity Incentive Plan of Infinity Pharmaceuticals, Inc. Exhibit 10.1 AMENDMENT NO. 1 TO 2019 EQUITY INCENTIVE PLAN OF INFINITY PHARMACEUTICALS, INC. The 2019 Equity Incentive Plan, as amended (the ?Plan?) of Infinity Pharmaceuticals, Inc. is hereby amended as follows: 1. Section 4(c) of the Plan is hereby deleted and new Sections 4(c) is inserted in lieu thereof which shall read as follows: ?(c) Awards to Non-Employee Directors. 1.Initial Grant. Upon t |
|
| March 29, 2022 |
EX-99.1 3 a202110kpressrelease.htm EX-99.1 Exhibit 99.1 Infinity Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Company Highlights – MARIO-4, the first eganelisib registration-enabling trial, in front-line metastatic triple negative breast cancer expected to initiate by the end of 2022 – –MARIO-P, a study designed to expand eganelisib development in additional solid tumor in |
|
| March 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-3114 |
|
| March 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 25, 2022 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Comm |
|
| February 14, 2022 |
INFI / Infinity Pharmaceuticals Inc. / Polar Capital Holdings Plc Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Infinity Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45665G303 (CUSIP Number) Dec |
|
| February 14, 2022 |
INFI / Infinity Pharmaceuticals Inc. / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Infinity Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45665G303 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| February 10, 2022 |
INFI / Infinity Pharmaceuticals Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Infinity Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 45665G303 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d- |
|
| January 18, 2022 |
INFI / Infinity Pharmaceuticals Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) INFINITY PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 45665G303 (CUSIP Number) DECEMBER 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designa |
|
| January 5, 2022 |
Exhibit 99.1 Infinity Pharmaceuticals Outlines Eganelisib Clinical Development Strategy and Provides 2022 Guidance - MARIO-4 registration study in frontline metastatic triple negative breast cancer to be initiated by year end 2022 - - MARIO-P platform study in multiple solid tumors to be initiated on a rolling basis in 3Q 2022 - CAMBRIDGE, Mass. ? (BUSINESS WIRE) ? January 05, 2022 ? Infinity Phar |
|
| January 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 5, 2022 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Com |
|
| December 10, 2021 |
EX-99.1 2 ex991pr121020218-ksabcs.htm EX-99.1 Exhibit 99.1 Encouraging Updated Data from Phase 2 MARIO-3 TNBC Trial Presented at 2021 San Antonio Breast Cancer Symposium — 88.6% of Evaluable 1L TNBC Patients Achieved Tumor Reduction — — Disease Control Rate of 92.8% and 81.4% of Evaluable Patients with PD-L1 Positive and PD-L1 Negative Tumors, Respectively — — Median PFS Improvement of 47% and 30% |
|
| December 10, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 10, 2021 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (C |
|
| November 2, 2021 |
Offer Letter between the Registrant and Stephane Peluso, Ph.D., dated July 12, 2021 Exhibit 10.1 1100 Massachusetts Ave Cambridge, MA Tel: 617-453-1000 Fax: 617-453-1001 www.infi.com July 12, 2021 Stephane Peluso, Ph.D. 38 Algonquian Drive Natick, MA 01760 Dear Stephane, On behalf of Infinity Pharmaceuticals, Inc. (the ?Company?), I am pleased to offer you the position of Senior Vice President, Chief Scientific Officer reporting to Adelene Perkins, Chief Executive Officer. Effect |
|
| November 2, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 2, 2021 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Co |
|
| November 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file num |
|
| November 2, 2021 |
Exhibit 99.1 Infinity Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Company Update ? Encouraging data for eganelisib in both PD-L1(-) and PD-L1(+) mTNBC patients, with meaningful prolongation of PFS over IMpassion130 reference benchmark ? ? Updated mTNBC data to be presented at San Antonio Breast Cancer Symposium ? ? Encouraging data for eganelisib in mUC patients, with |
|
| November 2, 2021 |
As filed with the Securities and Exchange Commission on November 2, 2021 As filed with the Securities and Exchange Commission on November 2, 2021 Registration No. |
|
| November 2, 2021 |
Offer Letter between the Registrant and Robert Ilaria, Jr., M.D., dated August 11, 2021. Exhibit 10.2 1100 Massachusetts Ave Cambridge, MA Tel: 617-453-1000 Fax: 617-453-1001 www.infi.com August 11, 2021 Robert L. Ilaria, Jr., M.D. 9 Highview Terrace Madison, NJ 07940 Dear Robert, On behalf of Infinity Pharmaceuticals, Inc. (the ?Company?), I am pleased to offer you the position of Senior Vice President, Chief Medical Officer reporting to Adelene Perkins, Chief Executive Officer. In t |
|
| September 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 1, 2021 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (C |
|
| August 2, 2021 |
Form of Restricted Stock Unit Agreement. Exhibit 99.2 INFINITY PHARMACEUTICALS, INC. Restricted Stock Unit Agreement Inducement Grant Pursuant to Nasdaq Stock Market Rule 5635(c)(4) Infinity Pharmaceuticals, Inc. (the ?Company?) hereby grants the following restricted stock units. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of recipient (the ?Participant?): Grant Date: Number of restricted stock u |
|
| August 2, 2021 |
Form of Stock Option Award Agreement. Exhibit 99.1 INFINITY PHARMACEUTICALS, INC. Nonstatutory Stock Option Agreement Inducement Grant Pursuant to Nasdaq Stock Market Rule 5635(c)(4) 1. Grant of Option. This agreement (the ?Agreement?) evidences the grant by Infinity Pharmaceuticals, Inc. (the ?Company?) on [] (the ?Grant Date?) to [], an employee of the Company (the ?Participant?), of an option (the ?Option?) to purchase, on the term |
|
| August 2, 2021 |
As filed with the Securities and Exchange Commission on August 2, 2021 As filed with the Securities and Exchange Commission on August 2, 2021 Registration No. |
|
| July 27, 2021 |
TABLE OF CONTENTS As Filed Pursuant to Rule 424(b)(5) Registration No. 333-256096 PROSPECTUS SUPPLEMENT (To Prospectus Dated May 21, 2021) ? $75,000,000 Common Stock We have entered into an amendment, dated July 27, 2021, or the amendment, to the Amended and Restated Capital on Demand? Sales Agreement, dated July 29, 2019, or, as amended by the amendment, the sales agreement, with JonesTrading Ins |
|
| July 27, 2021 |
EX-99.1 2 a72721earningspressrelease.htm EX-99.1 Exhibit 99.1 Infinity Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Company Update –New clinical data from MARIO-275 and MARIO-3 suggest that the addition of eganelisib to standard of care regimens provides patient benefit – –Increases seen in overall survival in 2L urothelial cancer (UC) and in progression free survival |
|
| July 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: |
|
| July 27, 2021 |
Exhibit 10.2 INFINITY PHARMACEUTICALS, INC. Amendment No. 1 to Amended and Restated Capital on DemandTM Sales Agreement Sales Agreement July 27, 2021 JonesTrading Institutional Services LLC 757 Third Avenue, 23rd Floor New York, NY 10017 B. Riley Securities, Inc. 299 Park Avenue, 21st Floor New York, NY 10171 Ladies and Gentlemen: Reference is made to the Amended and Restated Capital on DemandTM S |
|
| July 27, 2021 |
Eganelisib Re-Programming Macrophages To Develop Best-In-Class Next-Generation Immunotherapies July 27, 2021 2 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements and information of Infinity Pharmaceuticals, Inc. |
|
| July 27, 2021 |
Exhibit 99.3 Infinity Pharmaceuticals Presents Updated Data from Phase 2 MARIO-275 Trial in Urothelial Cancer (UC) and Phase 2 MARIO-3 Trial in Triple Negative Breast Cancer (TNBC) ? MARIO-275 median overall survival data show combination of eganelisib with nivolumab achieves 15.4 months compared to 7.9 months on nivolumab control arm in 2L UC ? ? MARIO-3 TNBC early data suggest the addition of eg |
|
| July 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 27, 2021 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Commi |
|
| June 17, 2021 |
INFI / Infinity Pharmaceuticals Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment SC 13G 1 INFISC13G.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 INFINITY PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 45665G303 (CUSIP Number) JUNE 10, 2021 (Date of event which requires filing of this statement) Check the appropriate box to design |
|
| June 11, 2021 |
As filed with the Securities and Exchange Commission on June 11, 2021 Registration No. 333- As filed with the Securities and Exchange Commission on June 11, 2021 Registration No. |
|
| June 11, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 10, 2021 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Commi |
|
| May 19, 2021 |
May 19, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| May 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 13, 2021 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Commis |
|
| May 13, 2021 |
As filed with the Securities and Exchange Commission on May 13, 2021 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 13, 2021 Registration No. |
|
| May 13, 2021 |
Exhibit 99.1 Infinity Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Company Update ?Updated TNBC data from MARIO-3 to be reported mid-year and 4Q?21? ?Update for eganelisib in PD-L1 low, 2L advanced UC patients expected mid-year? ?$92M public offering strengthens balance sheet for continued development of eganelisib? CAMBRIDGE, Mass., May 13, 2021 /Business Wire/ - Infi |
|
| May 13, 2021 |
Exhibit 4.4 INFINITY PHARMACEUTICALS, INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 |
|
| May 13, 2021 |
Form of Subordinated Note (FACE OF SECURITY) EX-4.6 5 nt10024341x1ex4-6.htm EXHIBIT 4.6 Exhibit 4.6 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOS |
|
| May 13, 2021 |
Form of Senior Note (FACE OF SECURITY) EX-4.5 4 nt10024341x1ex4-5.htm EXHIBIT 4.5 Exhibit 4.5 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY |
|
| May 13, 2021 |
INFINITY PHARMACEUTICALS, INC. Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 EX-4.3 2 nt10024341x1ex4-3.htm EXHIBIT 4.3 Exhibit 4.3 INFINITY PHARMACEUTICALS, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.0 |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: |
|
| April 26, 2021 |
2013 Employee Stock Purchase Plan, as amended. TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.?) Filed by the Registrant ? ? ? Filed by a party other than the Registrant ?? Check the appropriate box: ?? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission Only (as permi |
|
| March 16, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 16, 2021 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Comm |
|
| March 16, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-3114 |
|
| March 16, 2021 |
Description of Securities Registered Under Section 12 of the Exchange Act EXHIBIT 4.2 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following description of the common stock, par value $0.001 per share (the ?Common Stock?) of Infinity Pharmaceuticals, Inc. (?us,? ?our,? ?we? or the ?Company?), which is the only security of the Company registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), summ |
|
| March 16, 2021 |
Exhibit 99.1 Infinity Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Update on Eganelisib Development – MARIO-275 data at ASCO GU demonstrate eganelisib benefits across ORR, DCR, and PFS in PD-L1 low, 2L advanced UC patients; planning registration enabling study – –MARIO-3 initial data at SABCS demonstrate tumor reduction in 100% of patients and an ORR of 69.2%, irrespective |
|
| February 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Infinity Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45665G303 (CUSIP Number) Febr |
|
| February 19, 2021 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated February 19, 2021 with respect to the shares of Common Stock, $0.001 par value of Infinity Pharmaceuticals, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 6)1 Infinity Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45665G303 (CUSIP Number) JAMES KRATKY BVF |
|
| February 12, 2021 |
INFINITY ANNOUNCES PRICING OF $80 MILLION PUBLIC OFFERING OF COMMON STOCK Exhibit 99.2 INFINITY ANNOUNCES PRICING OF $80 MILLION PUBLIC OFFERING OF COMMON STOCK CAMBRIDGE, Mass. - (BUSINESS WIRE) - Feb. 12, 2021 - Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (?Infinity? or the ?Company?), an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer, today announced the pricing of its previously announced underwritten public offe |
|
| February 12, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 11, 2021 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (C |
|
| February 12, 2021 |
Exhibit 1.1 21,000,000 Shares1 Infinity Pharmaceuticals, Inc. Common Stock PURCHASE AGREEMENT February 11, 2021 PIPER SANDLER & CO. As Representative of the several Underwriters named in Schedule I hereto c/o Piper Sandler & Co. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: Infinity Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), proposes t |
|
| February 12, 2021 |
INFINITY ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Exhibit 99.1 INFINITY ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK CAMBRIDGE, Mass. - (BUSINESS WIRE) - Feb. 11, 2021 - Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechani |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1) INFINITY PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45665G303 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| February 12, 2021 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-230258 PROSPECTUS SUPPLEMENT (To Prospectus dated April 29, 2019) 21,000,000 Shares Common Stock We are offering 21,000,000 shares of our common stock. Our common stock is listed on the Nasdaq Global Select Market under the symbol “INFI.” On February 11, 2021, the last reported sale price of our common stock on the Nasdaq Gl |
|
| February 11, 2021 |
As filed with the Securities and Exchange Commission on February 11, 2021 Registration No. |
|
| February 11, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 11, 2021 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (C |
|
| February 11, 2021 |
Exhibit 99.2 Infinity Pharmaceuticals Presents Data from Randomized, Placebo-Controlled, Phase 2 MARIO-275 Trial of Eganelisib and Nivolumab in Advanced Urothelial Cancer at ASCO Genitourinary Cancers Symposium - Combination of eganelisib with nivolumab demonstrated improved ORR, DCR, and PFS versus 2L standard of care nivolumab monotherapy - - 46% lower probability of progression on combination a |
|
| February 11, 2021 |
Subject to Completion, dated February 11, 2021 TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-230258 Subject to Completion, dated February 11, 2021 PRELIMINARY PROSPECTUS SUPPLEMENT (To Prospectus dated April 29, 2019) The information in this prospectus supplement and the accompanying prospectus is not complete and may be changed. This prospectus supplement and the accompanying prospectus are not an offer to sell these |
|
| February 11, 2021 |
EX-99.1 2 infiguascoinvestorfinal.htm EX-99.1 Eganelisib Macrophage Modulator as 2L Combination Therapeutic Candidate for Metastatic Urothelial Cancer and Other Solid Tumors February 11, 2021 Exhibit 99.1 2 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements and information of Infinity Pharmaceuticals, Inc. (“we,” “us,” “our,” “Infinity” or th |
|
| January 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Infinity Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45665G303 (CUSIP Number) January 22, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| January 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 5)1 Infinity Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45665G303 (CUSIP Number) JAMES KRATKY BVF |
|
| January 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 6, 2021 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Com |
|
| January 6, 2021 |
Exhibit 99.1 Infinity Pharmaceuticals Provides Update for Eganelisib in Patients with Metastatic Urothelial Cancer -Infinity Planning New, Registration-Enabling Study in Advanced Urothelial Cancer Leveraging Encouraging Data from MARIO-275- -MARIO-275 Data to be Presented at a Major Medical Meeting in Q1 2021- -Infinity Provides 2021 Milestones and Financial Guidance- CAMBRIDGE, Mass., January 6, |
|
| December 9, 2020 |
sabcsinvestorpresentaton Eganelisib First-in-Class PI3K-���� Inhibitor Targeting Immune Suppressive Myeloid Cells in Metastatic Triple-Negative Breast Cancer December 9, 2020 2 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. |
|
| December 9, 2020 |
Exhibit 99.2 Infinity Pharmaceuticals Presents Front-Line Triple Negative Breast Cancer Data from Ongoing Phase 2 MARIO-3 Trial at the 2020 San Antonio Breast Cancer Symposium -100% of Evaluable Patients Achieved Tumor Reduction Irrespective of PD-L1 Status- -69.2% of Evaluable Patients Achieved Best Responses of Complete Response or Partial Response- - Safety Consistent With Expectations Of Compo |
|
| December 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 7, 2020 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Co |
|
| November 12, 2020 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D dated April 12, 2018 (including amendments thereto) with respect to the Common Stock, $0.001 par value, of Infinity Pharmaceuticals, Inc. This Joint Filing Agree |
|
| November 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 4)1 Infinity Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45665G303 (CUSIP Number) JAMES KRATKY BVF |
|
| November 9, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 9, 2020 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Co |
|
| November 9, 2020 |
Exhibit 99.1 Infinity Pharmaceuticals Provides Company Update and Third Quarter 2020 Financial Results – MARIO-275 IDMC Determined that Risk/Benefit for Patients Warrants Resumption of Enrollment; Infinity to Determine Next Steps by Year End – – MARIO-3 Encouraging Data in Front-Line Triple Negative Breast Cancer Patients to be Presented at San Antonio Breast Cancer Symposium – – MARIO-1 Melanoma |
|
| November 9, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file num |
|
| November 9, 2020 |
Exhibit 99.2 Infinity Pharmaceuticals Presents New MARIO-1 Phase 1/1b Clinical Data at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting – Data from melanoma and SCCHN cohorts demonstrate eganelisib was well tolerated in combination with Opdivo® – –Translational data supports on-mechanism immune modulation – – Clinical activity in patients with two or fewer prior lines |
|
| September 29, 2020 |
Exhibit 99.1 Infinity Receives Fast Track Designation for Eganelisib in Combination with a Checkpoint Inhibitor and Chemotherapy for First-Line Treatment of Advanced TNBC CAMBRIDGE, Mass.—September 29, 2020 - Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for eganelisib (IPI-549) in combination with |
|
| September 29, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 29, 2020 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) ( |
|
| September 21, 2020 |
INFI / Infinity Pharmaceuticals, Inc. / Opaleye Management Inc. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 INFINITY PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45665G303 (CUSIP Number) September 9, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| August 25, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 24, 2020 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Com |
|
| July 30, 2020 |
Exhibit 99.1 Infinity Pharmaceuticals Provides Company Update and Second Quarter 2020 Financial Results – MARIO-275 Dose Reduction Effective in Reducing Liver Enzyme Elevations. Interim Efficacy Analysis Expected by Year End. – – Encouraging Early Clinical Activity in MARIO-3 Front-Line Triple Negative Breast Cancer Cohort to be Presented by Year End – – Cash Runway into 2H2021 – CAMBRIDGE, Mass., |
|
| July 30, 2020 |
Restated Certificate of Incorporation of the Registrant, as amended. Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF INFINITY PHARMACEUTICALS, INC. A Delaware Corporation INFINITY PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows: FIRST: The name of the corporation is Infinity Pharmaceuticals, Inc. The original Certificate of Incorporation of the corporation was filed with the offic |
|
| July 30, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 30, 2020 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Commi |
|
| July 30, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: |
|
| July 2, 2020 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 1, 2020 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Commis |
|
| June 18, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 17, 2020 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Commi |
|
| June 18, 2020 |
Certificate of Amendment of Restated Certificate of Incorporation of Infinity Pharmaceuticals, Inc. CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF INFINITY PHARMACEUTICALS, Inc. |
|
| June 4, 2020 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| May 11, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number |
|
| May 11, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 11, 2020 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Commis |
|
| May 11, 2020 |
Exhibit 99.1 Infinity Pharmaceuticals Provides Company Update and First Quarter 2020 Financial Results - Fast Track Designation Granted for IPI-549 Plus Opdivo® in Patients with Advanced Urothelial Cancer - - Infinity Voluntarily Pausing Enrollment on MARIO-275 to Evaluate the Risk/Benefit for Patients - - Completion of Enrollment for MARIO-275 and MARIO-3 Delayed with Outlook for Completion of En |
|
| April 27, 2020 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 7, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 7, 2020 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Commi |
|
| April 7, 2020 |
Infinity Pharmaceuticals Provides Update in Response to COVID-19 Pandemic Exhibit 99.1 Infinity Pharmaceuticals Provides Update in Response to COVID-19 Pandemic CAMBRIDGE, Mass., April 7, 2020 - Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today provided an update in response to the COVID-19 pandemic. The company has taken steps to ensure the safety of its patients and employees as well as the continued progress of its clinical programs. “The COVID-19 pandemic has crea |
|
| April 3, 2020 |
INFI / Infinity Pharmaceuticals, Inc. PRE 14A - - PRE 14A PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 25, 2020 |
Exhibit 99.1 Infinity Receives Fast Track Designation for IPI-549 in Combination with the Checkpoint Inhibitor Opdivo for the Treatment of Advanced Urothelial Cancer CAMBRIDGE, Mass., March 25, 2020 - Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for IPI-549 in combination with nivolumab (Opdivo®) f |
|
| March 25, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 25, 2020 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Comm |
|
| March 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 16, 2020 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Comm |
|
| March 17, 2020 |
Infinity Pharmaceuticals Augments Board of Directors with Appointment of Richard Gaynor, M.D. Exhibit 99.1 Infinity Pharmaceuticals Augments Board of Directors with Appointment of Richard Gaynor, M.D. CAMBRIDGE, Mass., March 17, 2020 - Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today the appointment of Richard Gaynor, M.D. to its Board of Directors, effective March 16, 2020. “We are thrilled to have Dr. Gaynor join the board as we advance IPI-549 to important data readouts,” s |
|
| March 3, 2020 |
INFI / Infinity Pharmaceuticals, Inc. 10-K - Annual Report - 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2019 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-3114 |
|
| March 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 27, 2020 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (C |
|
| March 3, 2020 |
EX-10.15 3 exhibit1015fundingagreement.htm EXHIBIT 10.15 EXHIBIT 10.15 Execution Version FUNDING AGREEMENT This Funding Agreement (this “Agreement”), dated as of January 8, 2020, is entered into by and among Infinity Pharmaceuticals, Inc., a Delaware corporation (the “Company”), BVF Partners L.P., a Delaware limited partnership (“BVF”) and Royalty Security, LLC, a wholly owned subsidiary of BVF an |
|
| March 3, 2020 |
Exhibit 99.1 Infinity Pharmaceuticals Reports Full Year 2019 Financial Results and Provides Company Update - Enrollment Completion for MARIO-275, Infinity’s Global, Randomized Phase 2 Study in Patients with Urothelial Cancer, Expected in 2020 with Data Expected in 2021 - - Initial Data from Phase 2 MARIO-3 Trial and Updated Data from Ongoing Phase 1b MARIO-1 Trial Expected in 2020 - - Cash Runway |
|
| March 3, 2020 |
Description of Securities Registered Under Section 12 of the Exchange Act EXHIBIT 4.2 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following description of the common stock, par value $0.001 per share (the “Common Stock”) of Infinity Pharmaceuticals, Inc. (“us,” “our,” “we” or the “Company”), which is the only security of the Company registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), summ |
|
| March 3, 2020 |
EX-10.16 4 exhibit1016fundingagreemen.htm EXHIBIT 10.16 EXHIBIT 10.16 Execution Version NOVATION AND AMENDMENT AGREEMENT This Novation and Amendment Agreement (this “Agreement”) is made as of January 27, 2020, by and among Infinity Pharmaceuticals, Inc. (the “Company”), BVF Partners L.P. (“BVF”), Royalty Security Holdings, LLC (“Holdco”), and Royalty Security, LLC (“Buyer”). Each of the Company, B |
|
| March 3, 2020 |
2013 Employee Stock Purchase Plan, as amended. EX-10.35 5 exhibit10352013esppasamend.htm EXHIBIT 10.35 EXHIBIT 10.35 INFINITY PHARMACEUTICALS, INC. 2013 EMPLOYEE STOCK PURCHASE PLAN The following constitute the provisions of the 2013 Employee Stock Purchase Plan of Infinity Pharmaceuticals, Inc. 1.Purpose. The purpose of the Plan is to provide employees of the Company and its Designated Subsidiaries with an opportunity to purchase Common Stock |
|
| March 3, 2020 |
Subsidiaries of the Registrant. EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT Name Jurisdiction of Organization Percentage Ownership Infinity Discovery, Inc. Delaware 100% Infinity Security Corporation Massachusetts 100% |
|
| January 13, 2020 |
EX-99.1 Exhibit 99.1 Infinity Pharmaceuticals Provides 2020 Goals and Financial Guidance - Recent Non-Dilutive Financing Extends Cash Runway into 2H 2021 and Fully Funds All Ongoing IPI-549 Clinical Trials Through Key Data Readouts - - MARIO-275 Global, Randomized, Controlled Phase 2 Study in Urothelial Cancer Enrollment Completion Expected in 2020 with Data Expected in Mid-2021 - - MARIO-3 Phase |
|
| January 13, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 13, 2020 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Co |
|
| January 10, 2020 |
SC 13D/A 1 sc13da307422inf01102020.htm AMENDMENT NO. 3 TO THE SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 3)1 Infinity Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par val |
|
| January 9, 2020 |
EX-99.1 Exhibit 99.1 Infinity Pharmaceuticals Raises $20 Million Through an Innovative Non-Dilutive Asset-Backed Financing from BVF — Fully funds all ongoing IPI-549 clinical trials through key data readouts — — Non-dilutive financing extends cash runway into 2H 2021 — CAMBRIDGE, Mass.—January 9, 2020 — Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity”) today announced a $20 million non-di |
|
| January 9, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 8, 2020 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Com |
|
| October 30, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 30, 2019 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Co |
|
| October 30, 2019 |
Exhibit 99.1 Infinity Pharmaceuticals Provides Company Update and Third Quarter 2019 Financial Results - MARIO-1 Enrollment Completion Expected in 2019 and Data Presentation Expected in 2020 - - MARIO-3 Enrollment Completion and Data Presentation Expected in 2020 - - MARIO-275 Enrollment Completion Expected in 2020 - CAMBRIDGE, Mass., October 30, 2019 /Business Wire/ - Infinity Pharmaceuticals, In |
|
| October 30, 2019 |
INFI / Infinity Pharmaceuticals, Inc. 10-Q - Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file num |
|
| August 22, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 16, 2019 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Commiss |
|
| August 22, 2019 |
EX-99.1 Exhibit 99.1 — Infinity Pharmaceuticals Announces Transition of Samuel Agresta, M.D., from Chief Medical Officer to Board of Directors — CAMBRIDGE, Mass., August 22, 2019 /PRNewswire/ — Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that Samuel Agresta, M.D., will transition from his role as Chief Medical Officer to Infinity’s Board of Directors and Research and Development |
|
| July 30, 2019 |
424B5 Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No. 333-230258 PROSPECTUS SUPPLEMENT (To Prospectus Dated April 29, 2019) $20,000,000 Common Stock We have entered into an Amended and Restated Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC and B. Riley FBR, Inc., each an Agent and collectively, the Agents, relating to shares of our common st |
|
| July 30, 2019 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 29, 2019 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporatio |
|
| July 30, 2019 |
EX-1.1 Exhibit 1.1 INFINITY PHARMACEUTICALS, INC. Shares of Common Stock (par value $0.001 per share) Amended and Restated Capital on DemandTM Sales Agreement July 29, 2019 JonesTrading Institutional Services LLC 757 Third Avenue, 23rd Floor New York, NY 10017 B. Riley FBR, Inc. 299 Park Avenue, 21st Floor New York, NY 10171 Ladies and Gentlemen: Reference is made to the Capital on DemandTM Sales |
|
| July 30, 2019 |
EX-99.1 Exhibit 99.1 Infinity Pharmaceuticals Provides Company Update and Second Quarter 2019 Financial Results — Initiated MARIO-275 Global, Randomized Phase 2 Study in I/O Naïve Urothelial Cancer — — Initiating MARIO-3 Phase 2 Study in Front-Line Triple Negative Breast and Renal Cell Cancer in 3Q — CAMBRIDGE, Mass., July 30, 2019 /PRNewswire/ — Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today |
|
| July 30, 2019 |
2013 Employee Stock Purchase Plan, as amended. Exhibit 10.4 AMENDMENT NO. 3 TO 2013 EMPLOYEE STOCK PURCHASE PLAN OF INFINITY PHARMACEUTICALS, INC. The 2013 Employee Stock Purchase Plan (the “Plan”) of Infinity Pharmaceuticals, Inc. is hereby amended as follows: 1.Section 12(a) of the Plan is hereby deleted and a new Section 12(a) is inserted in lieu thereof which shall read as follows: “(a) The maximum number of shares of the Common Stock whic |
|
| July 30, 2019 |
Form of Stock Option Agreement under 2019 Equity Incentive Plan. Exhibit 10.3 INFINITY PHARMACEUTICALS, INC. STOCK OPTION AGREEMENT Infinity Pharmaceuticals, Inc. (the “Company”) hereby grants the following stock option pursuant to its 2019 Equity Incentive Plan. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of optionee (the “Participant”): Grant Date: Incentive Stock Option or Nonstatutory Stock Option: Number of shares |
|
| July 30, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 0 |
|
| June 28, 2019 |
EX-1.1 Exhibit 1.1 INFINITY PHARMACEUTICALS, INC. Shares of Common Stock (par value $0.001 per share) Capital on DemandTM Sales Agreement June 28, 2019 JonesTrading Institutional Services LLC 757 Third Avenue, 23rd Floor New York, NY 10017 Ladies and Gentlemen: Infinity Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Intern |
|
| June 28, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 d741496d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 28, 2019 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-31141 33-0655706 (State or other jurisdiction |
|
| June 28, 2019 |
424B5 1 d766804d424b5.htm 424B5 Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No. 333-230258 PROSPECTUS SUPPLEMENT (To Prospectus Dated April 29, 2019) $20,000,000 Common Stock We have entered into a Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC, or JonesTrading, relating to shares of our common stock offered by this prospectus. In accordance |
|
| June 14, 2019 |
INFI / Infinity Pharmaceuticals, Inc. S-8 - - S-8 S-8 As filed with the Securities and Exchange Commission on June 14, 2019 Registration No. |
|
| June 13, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 13, 2019 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Commi |
|
| May 7, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 7, 2019 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Commiss |
|
| May 7, 2019 |
EX-99.1 Exhibit 99.1 Infinity Pharmaceuticals Provides Company Update and First Quarter 2019 Financial Results — MARIO-275 Phase 2 Study in I/O Naïve Urothelial Cancer Patients on Track to Initiate in 2Q19 — — MARIO-3 Phase 2 Study in Front-Line Triple Negative Breast Cancer and Renal Cell Cancer Patients on Track to Initiate in 3Q19 — — Infinity Received Net Proceeds of $22.9M in Non-Dilutive Cap |
|
| May 7, 2019 |
Execution Version PROTECTIVE RIGHTS AGREEMENT THIS PROTECTIVE RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of March 11, 2019 by and between Infinity Pharmaceuticals, Inc. |
|
| May 7, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number |
|
| May 7, 2019 |
Lease Agreement, dated April 3, 2019, between Registrant and Sun Life Assurance Company of Canada. OFFICE LEASE 1100 MASSACHUSETTS AVENUE, CAMBRIDGE, MA Landlord: Sun Life Assurance Company of Canada Tenant: Infinity Pharmaceuticals, Inc. |
|
| May 7, 2019 |
Execution Version PURCHASE AND SALE AGREEMENT dated as of March 5, 2019 between INFINITY PHARMACEUTICALS, INC. |
|
| May 7, 2019 |
AMENDMENT No. 4 TO AMENDED AND RESTATED DEVELOPMENT AND LICENSE AGREEMENT This Amendment No. 4 to Amended and Restated Development and License Agreement (“Amendment No. 4”) is made as of this 4th day of March, 2019 (the “Amendment No. 4 Effective Date”) by and between Intellikine LLC, a limited liability company organized and existing under the laws of the State of Delaware and successor to Intell |
|
| April 25, 2019 |
INFI / Infinity Pharmaceuticals, Inc. CORRESP - - CORRESP April 25, 2019 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| April 24, 2019 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 8, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 5, 2019 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Commissio |
|
| March 14, 2019 |
Form of Subordinated Indenture EX-4.4 Exhibit 4.4 INFINITY PHARMACEUTICALS, INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE 1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314 |
|
| March 14, 2019 |
EX-4.3 Exhibit 4.3 INFINITY PHARMACEUTICALS, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.0 |
|
| March 14, 2019 |
INFI / Infinity Pharmaceuticals, Inc. S-3 S-3 Table of Contents As filed with the Securities and Exchange Commission on March 14, 2019 Registration No. |
|
| March 14, 2019 |
EX-4.6 Exhibit 4.6 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER N |
|
| March 14, 2019 |
EX-4.5 Exhibit 4.5 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE |
|
| March 14, 2019 |
EX-99.1 Exhibit 99.1 Infinity Pharmaceuticals Reports Full Year 2018 Financial Results and Provides Company Update — Copiktra™ Royalty Monetization for $30M in Gross Proceeds — — Roche/Genentech Clinical Collaboration on MARIO-3 in Front-Line Triple Negative Breast Cancer and Renal Cell Cancer — — BMS Clinical Collaboration on MARIO-275, a Randomized Study of IPI-549 and Opdivo® (nivolumab) in I/O |
|
| March 14, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 14, 2019 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Comm |
|
| March 14, 2019 |
Subsidiaries of the Registrant. Filed herewith. EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT Name Jurisdiction of Organization Percentage Ownership Infinity Discovery, Inc. Delaware 100% Infinity Security Corporation Massachusetts 100% |
|
| March 14, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2018 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-3114 |
|
| March 6, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 4, 2019 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Commi |
|
| March 6, 2019 |
EX-99.1 Exhibit 99.1 Infinity Pharmaceuticals Announces Royalty Monetization of COPIKTRA™ for $30 Million Gross Proceeds – Infinity Retains $22.5 Million in Gross Proceeds After Sharing with Takeda – Cambridge, MA – March 6, 2019 – Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today a royalty monetization with HealthCare Royalty Partners (HCR) for the right to receive certain royalty pay |
|
| January 28, 2019 |
8-K 1 d666025d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 26, 2019 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 000-31141 33-0655706 (State or other jurisdiction |
|
| January 7, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 7, 2019 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) |
|
| January 7, 2019 |
EX-99.1 Exhibit 99.1 Infinity Pharmaceuticals Provides 2019 Goals and Financial Guidance -IPI-549 Safety and Clinical Activity Support Initiation of Studies in Earlier Lines of Cancer Therapy with Double and Triple Combination Regimens- -MARIO-275:Global, Randomized Study of IPI-549 and Opdivo in I/O Naïve Urothelial Cancer- -Phase 1b Study of Novel Triple Combination Therapy in Advanced TNBC with |
|
| November 21, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 2)1 Infinity Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45665G303 (CUSIP Number) JAMES KRATKY BVF |
|
| November 5, 2018 |
EX-99.2 Exhibit 99.2 Bristol-Myers Squibb and Infinity Pharmaceuticals Announce a New Clinical Collaboration to Evaluate Opdivo (Nivolumab) in Combination with IPI-549 in Urothelial Cancer – Plans to Initiate MARIO-275, a Randomized, Global Phase 2 Study in 1H’19 – NEW YORK and Cambridge, MA – November 5, 2018 – Bristol-Myers Squibb Company (NYSE: BMY) and Infinity Pharmaceuticals, Inc. (NASDAQ: I |
|
| November 5, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 5, 2018 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Commis |
|
| November 5, 2018 |
EX-99.1 Exhibit 99.1 Infinity Pharmaceuticals Provides Company Update and Third Quarter 2018 Financial Results – Plans to Initiate IPI-549 MARIO-275, a Randomized, Global Phase 2 Study in Urothelial Cancer in Clinical Collaboration with Bristol-Myers Squibb – – Late-Breaking Presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting of Data from Combination Expansion Cohorts of |
|
| November 5, 2018 |
INFI / Infinity Pharmaceuticals, Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file num |
|
| November 5, 2018 |
EXHIBIT 10.2 AMENDMENT NO. 1 TO INFINITY PHARMACEUTICALS, INC. EXECUTIVE SEVERANCE BENEFITS PLAN The Executive Severance Benefits Plan (the “Plan”) of Infinity Pharmaceuticals, Inc. is hereby amended as follows: 1.Section 3(h) of the Plan is hereby deleted and a new Section 3(h) is inserted in lieu thereof which shall read as follows: “(h) “Covered Employees” shall mean all Regular Full‑Time Emplo |
|
| November 5, 2018 |
Offer Letter between the Registrant and Samuel Agresta, M.D., dated July 19, 2018. EXHIBIT 10.1 July 19, 2018 Samuel Agresta 24 Coolidge Avenue Lexington, MA 02420 Dear Sam, On behalf of Infinity Pharmaceuticals, Inc. (the “Company”), I am pleased to offer you the position of Senior Vice President, Chief Medical Officer reporting to Adelene Perkins, Chief Executive Officer. Effective Date: The effective date of your full-time employment with the Company shall be August 6, 2018. |
|
| October 1, 2018 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 24, 2018 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Comm |
|
| October 1, 2018 |
EX-99.1 Exhibit 99.1 INFINITY PHARMACEUTICALS EARNS $22 MILLION PAYMENT FROM VERASTEM ONCOLOGY FOR FDA APPROVAL OF COPIKTRATM (DUVELISIB) AND UPDATES 2018 FINANCIAL GUIDANCE Cambridge, MA – October 1, 2018 – Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that it earned a $22 million payment from Verastem Oncology under the license agreement between the Company and Verastem for COPIK |
|
| August 7, 2018 |
EX-99.1 Exhibit 99.1 Infinity Pharmaceuticals Provides Company Update and Second Quarter 2018 Financial Results –Dr. Samuel Agresta Appointed as Chief Medical Officer – –More Mature Data from Combination Expansion Cohorts of the On-Going IPI-549 MARIO-1 Phase 1/1b Study Expected in the Second Half of 2018 – Cambridge, Mass. – August 7, 2018 – Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today ann |
|
| August 7, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 7, 2018 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) |
|
| August 7, 2018 |
INFI / Infinity Pharmaceuticals, Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 0 |
|
| June 26, 2018 |
EX-99.1 Exhibit 99.1 Arcus Biosciences and Infinity Pharmaceuticals Announce Clinical Collaboration to Evaluate Lead Programs in Triple-Combination Studies - IPI-549 with AB928 and AB122 in Triple Negative Breast Cancer and Ovarian Cancer - - IPI-549 with AB928 and Chemotherapy in Triple Negative Breast Cancer and Ovarian Cancer - HAYWARD, Calif. and CAMBRIDGE, Mass., June 26, 2018 – Arcus Bioscie |
|
| June 26, 2018 |
Financial Statements and Exhibits, Other Events FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 25, 2018 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) ( |
|
| June 21, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 Infinity Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45665G303 (CUSIP Number) JAMES KRATKY BVF |
|
| June 14, 2018 |
Submission of Matters to a Vote of Security Holders 8-K 1 d609467d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 12, 2018 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of |
|
| May 8, 2018 |
EX-99.1 Exhibit 99.1 Infinity Pharmaceuticals Provides Company Update and First Quarter 2018 Financial Results – Company to Present Data from Combination Dose Escalation Component of Study at American Society of Clinical Oncology Annual Meeting (ASCO) – – Company Also to Provide an Update at ASCO on the Monotherapy Portion of the Trial and Initial Data from Combination Expansion Cohorts Initiated |
|
| May 8, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 8, 2018 Infinity Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 000-31141 33-0655706 (State or other jurisdiction of incorporation) (Co |
|
| May 8, 2018 |
INFI / Infinity Pharmaceuticals, Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number |
|
| May 8, 2018 |
INFI / Infinity Pharmaceuticals, Inc. CORRESP CORRESP May 8, 2018 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| April 30, 2018 |
INFI / Infinity Pharmaceuticals, Inc. S-3 S-3 1 d577519ds3.htm S-3 Table of Contents As filed with the Securities and Exchange Commission on April 30, 2018 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INFINITY PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 33-0655706 (State or Other Juris |
|
| April 25, 2018 |
INFI / Infinity Pharmaceuticals, Inc. DEF 14A DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 12, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 Infinity Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45665G303 (CUSIP Number) JAMES KRATKY BVF |
